Welcome to the post-event wrap-up of the largest Antibody Engineering & Therapeutics Europe event to date. On 6 – 8 June 2023 350+ attendees from across the antibody community gathered in Amsterdam to discuss the latest cutting-edge research and discover leading technologies. Keynote speakers included Marina Bacac Ph.D., Head of Cancer Immunotherapy Dept at Roche pRED, Suzan Rooijakkers Ph.D., Professor at UMC Utrecht, Geoff Hale Ph.D., CEO at mAbsolve, Thom Sharp Ph.D., Associate Professor and Leiden University Medical Center, and Kerry Chester Ph.D., Professor of Molecular Medicine at UCL Cancer Institute.
Antibody Engineering & Therapeutics Europe brings together peers from across the globe to discuss the critical updates in the antibody discovery, design and selection landscape – with the goal of providing actionable insights that will accelerate next generation antibodies to commercial success. The 2023 agenda focussed on 9 topic areas including: Antibody and VHH Discovery and Optimization, Conditionally Active Biotherapeutics, Agonist Antibodies, Immunocytokines, Immunotherapy and T-Cell Engagers, Novel ADC Technology, Machine Learning in Antibody Engineering, Applications of Fc Domain Engineering, and The Emergence of Bispecific and Multispecific Antibodies.
This eBook will showcase the highlights of the event and look at the significance of the research and insights shared throughout the 3 days in Amsterdam. Read on to get a sense of what the buzz is like on-site and learn more about the industry-shaping discussions that are shared at Antibody Engineering & Therapeutics Europe.
We hope to see you next year at Antibody Engineering & Therapeutics Europe 2024 – where we will be moving to London from 4 – 6 June!